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The availability of hepatitis B immune globulin (HBIG)
and several oral antiviral therapies has reduced but
not eliminated hepatitis B virus (HBV) recurrence. We
aimed to determine the rate of HBV recurrence after
orthotopic liver transplantation (OLT) in relation to vi-
rologic breakthrough pre-OLT and HBIG regimens post-
OLT. Data from the NIH HBV-OLT database were ana-
lyzed. A total of 183 patients transplanted between
2001 and 2007 followed for a median of 42 months
(range 1–81) post-OLT were studied. At transplant, 29%
were hepatitis B e antigen (HBeAg) (+), 38.5% had HBV
DNA > 5 log10 copies/mL, 74% were receiving antivi-
ral therapy. Twenty-five patients experienced virologic
breakthrough before OLT. Post-OLT, 26%, 22%, 40% and
12% of patients received intravenous (IV) high-dose,
IV low-dose, intramuscular low-dose and a finite du-
ration of HBIG, respectively as maintenance prophy-
laxis. All but two patients also received antiviral ther-
apy. Cumulative rates of HBV recurrence at 1 and 5
years were 3% and 9%, respectively. Multivariate anal-
ysis showed that listing HBeAg status and HBV DNA
level at OLT were the only factors associated with HBV
recurrence. In conclusion, low rates of HBV recurrence
can be accomplished with all the HBIG regimens used
when combined with antiviral therapy including pa-
tients with breakthrough pre-OLT as long as rescue
therapy is administered pre- and post-OLT.
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Introduction
The introduction of high-dose intravenous (IV) hepatitis B
immune globulin (HBIG) monotherapy reduced the 3-year
hepatitis B virus (HBV) recurrence rate after orthotopic liver
transplantation (OLT) from 80% to 36% (1). However, HBIG
monotherapy has limited efficacy in patients with high lev-
els of HBV replication pretransplant, is very expensive, and
may select for immune escape mutants (2–4). In the study
by Samuel et al., the overall 3-year HBV recurrence rate
among hepatitis B e antigen (HBeAg) and HBV DNA pos-
itive patients transplanted for cirrhosis was 83% (1). Mc-
Gory et al. (5) and Dickson et al. (6) observed that the
half-life of HBIG was shorter in patients who were HBeAg
positive or had detectable serum HBV DNA at the time of
transplantation highlighting the importance of suppressing
HBV replication prior to OLT.
Addition of oral antiviral agents to HBIG has resulted in a
further decrease in HBV recurrence rates to <10% (7–9).
Long-term administration of nucleos(t)ide analogs is asso-
ciated with an increasing risk of antiviral drug resistance
prior to OLT (10–13). However, several studies have re-
ported that patients with antiviral resistance prior to OLT
can be safely transplanted provided that rescue therapy is
administered (14–16).
With the availability of multiple nucleos(t)ide analogs, an
important question is how much HBIG is needed to prevent
HBV recurrence, when used in combination with antiviral
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therapy. Many investigators have explored low-dose HBIG
regimens or HBIG withdrawal (17–20) but the duration of
posttransplant follow-up was short (1–3 years) in many
studies and rescue therapy for patients with lamivudine-
resistant HBV was not uniformly available in studies con-
ducted prior to 2003.
The National Institutes of Health study on ‘Prevention of
HBV Recurrence after Liver Transplantation’ (NIH HBV-OLT
Study) is a retrospective–prospective observational study
involving 15 liver centers in the United States. The study
provided guidelines on the management of patients be-
fore and after OLT but each center was allowed to follow
its own HBIG protocol. The aims of this study were (i) to
determine the HBV recurrence rates in an era when antivi-
ral therapy is used in combination with HBIG and rescue
therapy is available for patients with lamivudine resistance,
(ii) to analyze the factors associated with HBV recurrence
post-OLT and (iii) to describe the HBIG regimens used in
U.S. liver transplant centers and the impact of different
HBIG regimens on HBV recurrence post-OLT.
Materials and Methods
Patient population
The NIH HBV-OLT study enrolled hepatitis B surface antigen (HBsAg) pos-
itive patients who were 13 years of age or older from 15 centers in the
United States (21). The study was approved by the Institutional Review
Board representing each of the participating centers, and written informed
consent was obtained from all patients prior to study entry.
A total of 317 patients were enrolled. Patients were listed between 1993
and 2005; 18 were listed prior to approval of lamivudine (December 1998)
and 151 were listed after approval of adefovir (ADV) (September 2002). For
this analysis, patients still on the transplant waiting list (n = 109), those
listed for retransplantation (n = 17) and those with less than 1 month of
posttransplant follow-up (n = 4) were excluded. Demographics, clinical, lab-
oratory (blood counts, creatinine, liver panel, prothrombin time/international
normalized ratio [INR], alpha-fetoprotein [AFP], hepatitis B serology and HBV
DNA), and radiologic data, as well as start and stop dates of antiviral therapy
and HBIG dosing, were recorded. Data were collected at enrollment, trans-
plant listing and time of transplant, every 6 months while on the transplant
waiting list, every 3 months during the first year posttransplant and every
6 months after the first posttransplant year. Data up to the time of study
closure on November 30, 2007 were analyzed.
At each visit, an extra tube of blood was collected for testing at a central
laboratory at the University of Michigan.
HBV DNA assay
All laboratory tests except for HBV DNA, antiviral- and HBIG-resistant muta-
tions were performed at the participating centers. Serum HBV DNA levels
were quantified by the Cobas Amplicor HBV Monitor assay (Roche Molecu-
lar Systems, Inc., Branchburg, NJ). The lower limit of detection of this assay
is 200 copies/mL. Samples with values >100,000 copies/mL were diluted
and retested. For patients with missing central laboratory samples, HBV
DNA results at the participating centers were used.
HBIG and HBV antiviral resistance mutation testing
All pretransplant samples from patients with detectable HBV DNA after ≥6
months of antiviral therapy were tested for antiviral drug-resistance muta-
tions and all posttransplant samples with detectable HBV DNA were tested
for both antiviral drug-resistance and HBIG escape mutations by direct se-
quencing of the HBV polymerase gene which overlaps with the surface
gene (22). Antiviral drug-resistance mutations were also tested by a line
probe assay (INNO-LiPA DRv2 and DRv3 [Innogenetics, Ghent, Belgium]),
which can detect mutations known to be associated with resistance to
lamivudine, ADV or ETV (23,24).
Definitions and HBIG regimens
Virologic breakthrough during antiviral therapy was defined as ≥1 log in-
crease in serum HBV DNA from nadir or redetection of HBV DNA in serum
after its initial disappearance. Genotypic resistance was defined as detec-
tion of amino acid substitutions in the HBV polymerase gene or the HBV
surface protein that had been documented to be associated with resistance
to HBV nucleos(t)ide analogues and HBIG, respectively. Recurrent HBV was
defined as the reappearance of HBsAg in serum after the first month post-
transplant. Patients were classified into four groups according to the dose
and duration of HBIG received: (1) high dose IV HBIG: 10 000 IU during the
anhepatic phase, daily for the next 6 days, and monthly thereafter; (2) low
dose IV HBIG: 3000—6000 IU monthly or 10 000 IU every 2–6 months; (3)
intramuscular (IM) HBIG: 1000 – 1500 IU every 1–2 months; and (4) finite
duration of HBIG: HBIG discontinued after a varying period.
Statistical analyses
Categorical data were presented as number and percent and compared
using chi-square test or Fisher’s exact test as appropriate. Continuous vari-
ables were expressed as mean and standard deviation (SD) unless speci-
fied otherwise, and were compared using t-test or Mann–Whitney U-test.
Serum HBV DNA level was expressed as copies/mL and logarithmically
transformed. Continuous variables were dichotomized taking the median
as cutoff value, except for serum HBV DNA, where the cutoff used was 5
log10 copies/mL. Univariate analyses of factors associated with HBV recur-
rence posttransplant were performed using Kaplan–Meier analysis with log
rank test. For this purpose patient demographics, OLT indication at the time
of transplant, use of antiviral therapy, occurrence of virologic breakthrough
and/or presence of genotypic resistance prior to transplant, transplant cen-
ter, type of HBIG regimen used, HBeAg status and HBV DNA level at listing
and at transplant and OLT date (before or after ADV approval) were analyzed.
Variables that had a p-value of <0.2 on univariate analysis were entered into
a Cox regression proportional hazards model. Forward and backward logis-
tic regression was performed to determine the independent predictors of
HBV recurrence. All statistical analyses were performed using SPSS version
14.0.8 statistical software (SPSS, Inc., Chicago, IL).
Results
Characteristics of patients
A total of 187 patients transplanted between March
2001 and September 2007 were included in this analysis.
Table 1 summarizes the characteristics of these patients at
the time of listing and at transplantation. The vast majority
(75.4%) of the patients were men and their mean age was
52.4 years. Asians comprised 42.8% of the patient popu-
lation, Caucasians 41.7% and African Americans 10.2%.
Coinfection with hepatitis C virus (HCV) was diagnosed
in 6.1% (10/164) while coinfection with hepatitis D virus
(HDV) was diagnosed in 7.5% (4/53) of patients tested. At
listing, 30.9% of the patients were HBeAg positive, 48.2%
had detectable serum HBV DNA and 30.4% had HBV DNA
>5 log10 copies/mL. The median interval between list-
ing and transplant was 3.0 months (range 0.03–97.5). At
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Table 1: Characteristics of patients at listing and at the time of transplant
End-stage cirrhosis HCC1 Acute liver failure All p-Value
No. of patients 73 (39.3) 97 (51.8) 17 (8.9) 187 (100)
Gender, male 58 (79.5) 75 (77.3) 8 (47.1) 141 (75.4) 0.013
Age, years 50.6 ± 8.1 55.5 ± 9.6 43.0 ± 14.2 52.4 ± 10.2 0.001
Race 0.005
Caucasian 33 (45.2) 36 (37.1) 9 (53.0) 78 (41.7)
Asian 23 (31.5) 53 (54.6) 4 (23.5) 80 (42.8)
African American 10 (13.7) 5 (5.2) 4 (23.5) 19 (10.2)
Other 7 (9.6) 3 (3.1) 0(0) 10 (5.3)
Labs at listing
HBeAg (+) 20/67 (29.8) 25/84 (29.7) 6/14 (42.9) 51/165 (30.9) 0.600
HBV DNA detectable 31/66 (47.0) 42/85 (49.4) 8/17 (47.1) 81/168 (48.2) 0.952
HBV DNA >5 log10 copies/mL 16/66 (24.2) 31/85 (36.5) 4/17 (23.5) 51/168 (30.4) 0.218
CTP Score 9.7 ± 2.2 7.7 ± 2.5 12.0 ± 1.7 9.1 ± 2.6 <0.001
Lab MELD 19.7 ± 8.7 13.1 ± 7.1 30.4 ± 5.9 18.4 ± 9.1 <0.001
Anti-HCV (+) 5/66 (7.6) 5/81 (6.2) 0/17 (0) 10/164 (6.1) 0.507
Anti-HDV (+) 3/25 (12.0) 1/23 (4.3) 0/5 (0) 4/53 (7.5) 0.483
Time on the waiting list, months 5 (0.1–84.0) 3 (0.1–97.5) 0.06 (0.03–0.27) 3.0 (0.03–97.5) 0.034
Labs at transplantation
HBeAg (+) 18/63 (28.6) 21/79 (26.6) 5/12 (41.7) 44/154 (28.6) 0.559
HBV DNA detectable 48/68 (70.6) 45/80 (56.3) 13/17 (76.5) 106/165 (64.2) 0.104
HBV-DNA >5 log10 copies/mL 22/68 (32.3) 33/80 (41.3) 7/17 (41.2) 62/165 (37.5) 0.077
HBV DNA >3 log10 copies/mL 35/68 (51.5) 39/80 (48.7) 12/17 (70.5) 86/165 (52.1) 0.259
HBV-DNA, log10 copies/mL 4.0 ± 2.2 4.1 ± 2.2 4.6 ± 2.1 4.1 ± 2.2 0.651
Albumin, g/dL 2.6 ± 0.6 3.2 ± 0.7 2.7 ± 0.6 2.9 ± 0.7 <0.001
AST, U/L 337 ± 862 154 ± 322 1212 ± 2133 323 ± 909 <0.001
ALT, U/L 258 ± 675 108 ± 203 1261 ± 2158 273 ± 841 <0.001
Bilirubin, mg/dL 10.4 ± 12.4 2.9 ± 5.4 20.7 ± 9.6 7.5 ± 10.7 <0.001
Alkaline phosphatase, U/L 146 ± 80.5 155 ± 111 137 ± 56.3 150 ± 96.0 0.716
INR 2.1 ± 1.5 1.3 ± 0.5 3.0 ± 1.7 1.8 ± 1.2 <0.001
CTP score 11.8 ± 3.1 7.7 ± 2.5 13 ± 1.4 10.1 ± 3.4 0.001
Lab MELD 24.5 ± 10.1 15.4 ± 8.1 32.1 ± 5.8 24.0 ± 9.5 <0.001
AFP, ng/mL 39.7 ± 215 453 ± 1538 68 ± 98 286 ± 1206 <0.001
Antiviral treatment at transplantation 56 (76.7) 75 (77.3) 7 (41.2) 138 (73.8) 0.006
Duration of antiviral treatment prior to OLT, months 19.8 ± 21.0 23.3 ± 21.8 0.1 ± 0.3 20.7 ± 21.4 0.021
Types of treatment 0.072
LAM 39 48 7 94
ADV 3 12 0 15
ETV 0 4 0 4
TDF 4 0 0 4
LAM+ADV 10 6 0 16
LAM+TDF 0 2 0 2
ETV+ADV 0 2 0 2
TDF+ADV 0 1 0 1
Virologic breakthrough prior to OLT 12/56 (21.4) 13/75 (17.3) 0/7 (0) 25/138 (18.1) 0.200
LAM 11 11 0 22
ADV 0 1 0 1
LAM+ADV 1 1 0 2
Results expressed as number (%) or mean ± SD unless specified otherwise.
LAM = lamivudine; ADV = adefovir; TDF = tenofovir; ETV = entecavir; HCC = hepatocellular carcinoma; CTP = child turcotte pugh;
MELD = model for endstage liver disease; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
1Patients found to have HCC while on the waiting list or at transplant were included in the HCC column.
transplantation, 28.6% of the patients were HBeAg pos-
itive, 64.2% had detectable serum HBV DNA and 37.5%
had HBV DNA >5 log10 copies/mL.
At listing, 98 (52.5%) patients had end-stage cirrhosis, 72
(38.6%) had hepatocellular carcinoma (HCC) and 17 (8.9%)
had acute liver failure. Twenty-five (25.5%) patients with
end-stage cirrhosis were diagnosed to have HCC while on
the transplant waiting list or on the explant liver. Thus, a
total of 97 (51.8%) patients had HCC while 73 (39.3%) had
end-stage cirrhosis with no HCC at the time of transplant
(Table 1).
American Journal of Transplantation 2010; 10: 1823–1833 1825
Degertekin et al.
Table 2: Characteristics of patients according to HBIG regimens
IV high dose IV low dose IM low dose Finite duration All p-Value
No. of patients 47 (25.6) 40 (21.8) 73 (39.8) 23 (12.8) 183 (100)
Gender, male 40 (85) 26 (65) 54 (74) 17 (74) 137 (74.9) 0.172
Age, years 51.7 ± 10.6 54.1 ± 9.7 53.3 ± 10.3 48.8 ± 10.0 52.3 ± 10.3 0.212
OLT indication at transplantation 0.214
Cirrhosis 18 (38.3) 16 (40) 22 (30) 14 (60.9) 70 (38.3)
HCC 26 (55.3) 20 (50) 44 (60.3) 6 (26.1) 96 (52.5)
Acute liver failure 3 (6.4) 4 (10) 7 (9.6) 3 (13) 17 (9.3)
Labs at listing
HBeAg (+) 16/44 (36.3) 8/34 (23) 19/62 (30) 8/23 (34.8) 51/163 (31.3) 0.289
HBV DNA detectable 26/43 (60.3) 18/38 (47.4) 26/61 (42) 11/23 (47.8) 81/165 (49.1) 0.418
HBV DNA, log10 copies/mL 4.0 ± 2.1 4.0 ± 2.3 3.4 ± 2.1 3.4 ± 2.0 3.73 ± 2.2 0.474
HBV DNA > 5 log10 copies/mL 16/45 (37.2) 15/38 (39.5) 17/61 (28) 3/23 (13) 51/165 (31) 0.154
Antiviral Rx at listing 27 (57.4) 23 (57.5) 40 (54.8) 12 (52.2) 102 (55.7) 0.992
Labs at transplantation
HBeAg (+) 12/41 (25.5) 9/33 (27) 16/58 (27.6) 7/21 (32.3) 44/153 (28.8) 0.924
HBV DNA detectable 28/44 (63.6) 23/38 (60) 38/56 (67) 16/23 (69.6) 105/161 (65.2) 0.888
HBV DNA, log10 copies/mL 4.6 ± 2.4 3.8 ± 2.2 4.4 ± 2.0 3.4 ± 1.8 4.2 ± 2.2 0.138
HBV DNA > 5 log10 copies/mL 21/44 (47.7) 12/38 (31.6) 25/56 (44.6) 4/23 (17.4) 62/161 (38.5) 0.080
Antiviral Rx at transplant 37 (78.7) 27 (67.5) 56 (76.7) 15 (65.2) 135 (73.8) 0.387
Breakthrough prior to OLT 8/37 (21.6) 5/27 (18.5) 10/56 (17.8) 2/15 (13.3) 25/135 (18.5) 0.576
Samples available 5/8 4/5 6/10 2/2 17/25
Confirmed genotypic resistance 5/5 (100) 3/4 (75) 4/6 (66) 2/2 (100) 14/17 (82.3)
Results expressed as number (%) or mean ± SD unless specified otherwise.
LAM = lamivudine; ADV = adefovir; TDF = tenofovir; ETV = entecavir; HCC = hepatocellular carcinoma.
Antiviral therapy and virologic breakthrough prior to
transplant
One-hundred and thirty-eight (73.8%) patients were receiv-
ing antiviral therapy at the time of transplantation: 117 were
receiving nucleos(t)ide monotherapy (including 94 patients
on lamivudine monotherapy) and 21 were receiving com-
bination therapy (Table 1). The mean duration of antiviral
therapy prior to OLT was 20.7 ± 21.4 months (maximum
94).
Twenty-five (18.1%) patients experienced virologic break-
through prior to transplantation. Genotypic resistance was
confirmed in 14 (58.3%) of 24 patients in whom serum
samples prior to initiation of rescue therapy were avail-
able for testing. Of the 25 patients with virologic break-
through, 24 received lamivudine monotherapy and one re-
ceived ADV monotherapy as their initial antiviral therapy
and breakthrough was diagnosed after a mean of 34.4 ±
18.5 months. Twenty patients received rescue therapy
with ADV (n = 4), lamivudine plus ADV (n = 12, including
one patient who had breakthrough while receiving ADV
monotherapy), TDF (n = 2), lamivudine plus TDF (n = 1) or
ETV (n = 1); five patients continued lamivudine monother-
apy. At the time of transplantation, serum HBV DNA was
detectable in all 24 patients tested and 18 had levels >5
log10 copies/mL.
HBV prophylaxis post-OLT and HBIG regimens
After transplantation, two patients received HBIG only and
four received antiviral therapy only while the remaining
patients received combination prophylaxis with HBIG and
antiviral therapy. Of the 185 patients who received antiviral
therapy post-OLT, 165 received nucleos(t)ide monotherapy:
lamivudine (n = 141 including four patients who received
antiviral prophylaxis only), ADV (n = 16), TDF (n = 3) or ETV
(n = 5). Twenty patients received combination antiviral ther-
apy, including 12 patients who had experienced virologic
breakthrough prior to transplantation.
The most common HBIG regimen was IM low dose (39%),
followed by IV high dose (25.1%), IV low dose (21.4%) and
finite duration of HBIG (12.3%). The last group of patients
had received HBIG for a median of 12 months (range 1–
48 months) and had been followed for a median of 53
months (range 6–66 months) after HBIG was discontin-
ued. The four groups were comparable regarding HBeAg
status, HBV DNA levels, use of antiviral therapy and viro-
logic breakthrough at the time of transplant (Table 2).
The HBIG regimens used in the 15 participating transplant
centers were highly variable not only across the centers
but also within the centers (Figure 1). The total HBIG dose
in year 1 ranged from 10 000 to 355 000 IU and in each
subsequent year from 0 to 200 000 IU.
Posttransplant outcomes
HBV recurrence: During a median follow-up of 42 months
(range 1–81 months) posttransplant, 13 (6.9%) patients
had HBV recurrence. Ten of the 13 patients had serum
samples collected after HBV recurrence was diagnosed
and prior to institution of rescue therapy. Of these, five
had mutations associated with resistance to lamivudine
(methionine to valine or isoleucine substitution at position
204 [rtM204V/I]), one had mutations associated with HBIG
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Figure 1: Distribution of HBIG regi-
mens used in each of the 15 partic-
ipating centers (A-O). Only 4 centers
(K, L, N, O) used one regimen. Number
of patients receiving each HBIG regi-
men: IV high dose, IV low dose, IM low
dose, and finite duration at each center
is listed beneath the bars.
resistance (glycine to arginine substitution at position 145
[sG145R]), three had mutations associated with resistance
to lamivudine and HBIG (rtM204V/I + sG145R), and one
had wild type HBV sequence. Among the five patients
with lamivudine resistance mutations only, three received
a finite duration of HBIG and HBV recurred 12, 14 and
33 months after discontinuation of HBIG. The other two
patients received high dose IV HBIG, both had HBV recur-
rence 1 month after transplant; one was documented to
have lamivudine resistance before transplant and had HBV
DNA of 8.6 log copies/mL at transplant while the other had
undetectable serum HBV DNA 3 months before transplant.
Both patients received lamivudine as the only antiviral ther-
apy posttransplant. All three patients who had mutations
associated with resistance to lamivudine and HBIG were
receiving lamivudine and IM HBIG. The patient with HBIG
resistance only had HBV DNA of 8.9 log copies/mL at trans-
plantation. This patient had lamivudine resistance prior to
transplantation and received prophylaxis with lamivudine,
ADV and IV HBIG but was later found to be non compliant.
The overall probability of HBV recurrence at 1, 3 and 5 years
posttransplant was 3%, 7% and 9%, respectively. The
probability of HBV recurrence at 1, 3 and 5 years posttrans-
plant was 1%, 6% and 9% among patients transplanted for
end-stage cirrhosis; and 6%, 8% and 11% among patients
transplanted for HCC; none of the patients transplanted
for acute liver failure had HBV recurrence (p = 0.686)
(Figure 2A).
Three (12%) of the 25 patients with virologic breakthrough
prior to transplantation had HBV recurrence compared to
eight (7.1%) of 113 patients who received antiviral therapy
but did not experience virologic breakthrough, and two
(4.1%) of 49 patients who did not receive antiviral ther-
apy prior to transplant. The 1-, 3- and 5-year probability of
HBV recurrence was 4%, 15% and 15% for patients with
and 3%, 6% and 8% for patients without virologic break-
through prior to transplant (p = 0.209) (Figure 2B).
Factors associated with HBV recurrence: Univariate
analysis showed that male gender (p = 0.031), Caucasian
race (p = 0.034), presence of HBeAg at listing (p = 0.01),
serum HBV DNA >5 log10 copies/mL at listing (p = 0.027)
and at transplantation (p = 0.003) were associated with
posttransplant HBV recurrence while transplant date be-
fore ADV approval (p = 0.077) showed a trend (Table 3,
Figure 2C and D). Virologic breakthrough prior to transplan-
tation, HBIG regimen, transplant center, duration of steroid
use and treatment for rejection were not associated with
HBV recurrence (Figure 2B and E).
Of the 97 patients who had HCC, HBV recurrence was
observed in two of 12 who had HCC recurrence and in six
of 85 who did not have HCC recurrence.
Among the 25 patients with virologic breakthrough prior
to transplantation, the three patients who had HBV recur-
rence differed from the other 22 patients who did not have
HBV recurrence in having higher serum HBV DNA at trans-
plantation (p = 0.094). Moreover, only one of the three pa-
tients with HBV recurrence received rescue therapy prior
to transplantation compared to 21 of 22 with no recurrence
(p = 0.031).
Cox regression analysis found that presence of HBeAg at
listing (HR: 11.6, 95% CI 1.36–99.7, p = 0.02) and serum
HBV DNA >5 log10 copies/mL at the time of transplant (HR:
7.0, 95% CI 1.03–47.28, p = 0.03) were the only factors
associated with posttransplant HBV recurrence while race
showed a trend (Table 4). The 1-, 3- and 5-year probability of
HBV recurrence was 10%, 15% and 15% for patients who
were HBeAg positive at listing and 0, 2% and 5% for those
who were HBeAg negative at listing (Table 5, Figure 2C).
The 1-, 3- and 5-year probability of HBV recurrence was
7%, 15% and 15% for patients with serum HBV DNA > 5
log10 copies/mL at transplant; 0%, 0% and 6% for those
with HBV DNA 3–5 log10 copies/mL; and 1%, 1% and 1%
for those with HBV DNA < 3 log10 copies/mL (Table 5).
Patient survival: A total of 17 (9%) patients (four of 13
patients with and 13 of 174 patients without HBV recur-
rence) died: two due to complications related to HBV re-
currence, five due to HCC recurrence, three due to other
liver causes, six due to nonliver causes and one due to an
unknown cause. The 1-, 3- and 5-year probability of post-
OLT patient survival for the entire cohort was 95%, 92%
and 90%, respectively. The probability of post-OLT survival
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Figure 2: (A) HBV recurrence in relation to indication at transplantation—The 1, 3, and 5 year probability of HBV recurrence
post-OLT was 1%, 6%, and 9% for patients with end-stage cirrhosis; and 6%, 8%, and 11% for patients with HCC; and none for
patients with acute liver failure (p = 0.686). (B) HBV recurrence in patients with and without virological breakthrough pretransplant
(p = 0.209). (C) HBV recurrence in relation to HBeAg status at listing-–The 1, 3, and 5 year probability of HBV recurrence post-OLT was
10%, 15%, and 15% for patients who were HBeAg positive at listing; and 0, 2% and 5% for those who were HBeAg negative (p = 0.010).
(D) HBV recurrence in relation to serum HBV DNA level at the time of transplant-–The 1, 3, and 5 year probability of HBV recurrence
post-OLT was 7%, 15%, and 15% for patients with serum HBV DNA >5 log10 copies/mL at transplant; and 1%, 1%, and 3% for those
with serum HBV DNA <5 log10 copies/mL (p = 0.003). (E) HBV recurrence in relation to HBIG regimens—The 5-year recurrence rates
for the groups that received IV high dose, IV low dose, IM low dose, and finite duration of HBIG were 10, 3, 10 and 14, respectively
(p = 0.733). The overall 5-year recurrence rate was 9%.
was lower among the patients with HBV recurrence (p =
0.028), but the difference was not significant when only
liver-related deaths were analyzed (p = 0.209) (Figure 3).
Of the four patients with HBV recurrence who died, one
died of liver failure related to recurrent HBV, one died from
postoperative complications after retransplantation for re-
current HBV and two died of nonliver related causes: brain
hemorrhage and primary lung cancer.
Discussion
In this study of 187 patients who had liver transplanta-
tion for hepatitis B in the U.S. between 2001 and 2007,
6.9% had HBV recurrence after a median follow-up of 42
months. All except six patients received combination pro-
phylaxis with HBIG and antiviral therapy. Most (>75%)
patients received lamivudine monotherapy while HBIG
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Table 3: Characteristics of patients with and without HBV recurrence
HBV recurrence No HBV recurrence p-Value
No. of patients 13 (6.9) 174 (93.0)
Gender, male 13 (100) 128 (73.6) 0.031
Age, years 53.5 ± 9.4 52.3 ± 10.3 0.708
Race 0.034
Caucasian 10 (76.9) 68 (39.2)
Asian 2 (15.4) 78 (44.8)
African American 1 (7.7) 18 (10.3)
Other 0 10 (5.7)
OLT Indication at transplant 0.686
End-stage cirrhosis 5 (38.5) 68 (39.1)
HCC 8 (61.5) 89 (51.1)
Acute liver failure 0 17 (9.8)
Labs at listing
HBeAg (+) 7/11 (63.6) 44/154 (28.6) 0.010
HBV DNA detectable 8/12 (66.7) 73/156 (46.8) 0.177
HBV DNA >5 log10 copies/mL 7/12 (58.3) 44/156 (28.2) 0.027
HBV-DNA log10 copies/mL 5.3 ± 2.98 3.50 ± 2.1 0.001
Labs at transplant
HBeAg (+) 4/9 (44.4) 40/145 (27.6) 0.220
HBV DNA detectable 9/10 (90) 97/155 (62.6) 0.103
HBV DNA >5 log10 copies/mL 8/10 (80) 54/155 (34.8) 0.003
HBV DNA >3 log10 copies/mL 9/10 (90) 77/155 (49.7) 0.017
HBV-DNA log10 copies/mL 7.0 ± 2.45 3.9 ± 2.0 <0.001
HBIG regimen 13/13 170/174 0.733
IV high dose 4 (30.7) 43 (25.3)
IV low dose 1 (7.7) 39 (22.9)
IM low dose 5 (38.5) 68 (40.0)
Finite duration 3 (23.0) 20 (11.8)
Antiviral treatment pre-OLT 11 (84.6) 127 (73.0) 0.285
Total duration of treatment before OLT, months 11.8 ± 9.2 21.4 ± 22.0 0.153
Treatment at the time of transplant 0.280
LAM 10/11 (90.9) 84/127 (66.1)
LAM+ADV/TDF 1/11 (9.1) 17/127 (13.5)
Non-LAM 0 26/127 (20.4)
Virologic breakthrough prior to OLT 3/11 (27.2) 22/127 (17.3) 0.209
Post-OLT prophylaxis 0.898
HBIG only 0 2 (1.1)
Antiviral only 0 4 (2.2)
HBIG+antiviral 13 (100) 168 (96.5)








Time of OLT (after 09.2002)1 6 (46.2) 130 (74.7) 0.077
Duration of steroid use (month) 4.42 ± 2.7 4.7 ± 5.0 0.809
Treatment for rejection 1 (7.6) 26 (14.6) 0.461
Results expressed as number (%) or mean ± SD unless specified otherwise.
LAM = lamivudine; ADV = adefovir; TDF = tenofovir; ETV = entecavir; HCC = hepatocellular carcinoma.
1Date when adefovir was approved.
regimens ranged from indefinite high dose IV to low dose
IM or finite duration. The 5-year recurrence rate of 9% is
lower than that in previous studies in which HBIG alone or
lamivudine alone was used as prophylaxis (1,9,25,26) but
higher than the 4% recurrence rate reported by Gane et al.
(27) The latter study was unique in that very low dose IM
HBIG was used from the time of transplantation (800 IU
daily × 1 week then monthly) in combination with lamivu-
dine. Two major differences between these two studies
may account for the slightly higher rate of HBV recurrence
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0.003 7.00 (1.03–47.28) 0.038
Race—non-
Caucasian





0.027 2.25 (0.39–13.0) 0.364
Center 0.202 0.98 (0.94–1.02) 0.387





0.077 0.84 (0.19–3.71) 0.818
Male gender 0.031 ∞1 0.800
1All patients in the HBV recurrence group were male.
in our study. Patients in our study had received a longer
duration of lamivudine therapy prior to transplant, median
276 versus 92 days and 25 patients in our study had experi-
enced virologic breakthrough before transplant. Moreover,
64% of our patients versus none in Gane’s study had de-
tectable HBV DNA at transplantation.
Indeed, high serum HBV DNA (>5 log10 copies/mL) at
transplantation and the presence of HBeAg at listing were
the only factors associated with HBV recurrence on mul-
tivariate analysis. High serum HBV DNA and presence of
HBeAg had been shown to decrease the half-life and ef-
ficacy of HBIG (5,6). The shortened half-life of HBIG be-
comes a greater problem in patients who had high serum
HBV DNA as a result of lamivudine resistance and who did
not receive rescue antiviral therapy posttransplant.
In this study, resistance to lamivudine and/or HBIG was
detected in nine of 10 patients for whom samples at the
time of HBV recurrence were available for testing. Muta-
tions associated with lamivudine resistance were detected
in eight patients; of these, three also had mutations asso-
ciated with HBIG resistance. One patient who was non-
compliant with antiviral medications had HBIG resistance
mutations only. Although antiviral and/or HBIG resistance
is the main cause of HBV recurrence, antiviral breakthrough
prior to transplant was not a significant predictor of HBV
recurrence. Of the 25 patients who were known to have vi-
rologic breakthrough prior to transplant, only three had HBV
recurrence, one due to noncompliance with antiviral med-
ications and two did not receive rescue antiviral therapy.
The remaining 22 patients including two who discontinued
Table 5: Probability of HBV recurrence after transplantation
Probability of HBV
recurrence
Year 1 Year 3 Year 5
Gender
Male 4 9 12
Female 0 0 0
Race
Caucasian 7 13 15
Asian 0 2 4
African American 6 6 6
Listing HBeAg status
HBeAg (+) 10 15 15
HBeAg (−) 0 2 5
Serum HBV DNA at OLT (log10
copies/mL)
>5 7 15 15
3–5 0 0 6
<3 1 1 1
OLT Date
Before 09/20021 4 13 15
After 09/2002 3 4 6
Indication at OLT
Cirrhosis 1 6 9
HCC 6 8 11
Acute liver failure 0 0 0
Antiviral breakthrough prior to OLT
Yes 4 15 15
No 3 6 8
HBIG regimen
IV high dose 7 10 10
IV low dose 3 3 3
IM low dose 3 6 10
Finite duration 0 9 14
Results expressed as percentage.
1Date when adefovir was approved.
HBIG and nine who received IM low dose HBIG had no ev-
idence of HBV recurrence up to 61 months posttransplant.
Our data confirmed the results of other investigators that
patients with antiviral resistance prior to transplant can be
safely transplanted provided that rescue therapy is admin-
istered (14–16).
The HBIG regimens used in this study varied not only
among the centers but also within each center. Many ex-
perts had suggested that prophylaxis against HBV recur-
rence be tailored to HBV replication status prior to trans-
plant (27–29). However, our study found that the type
of HBIG regimen used was not related to HBeAg sta-
tus, serum HBV DNA at transplantation or antiviral break-
through prior to transplantation indicating that other factors
such as institutional policies may be more important in de-
termining which HBIG regimen was used at each center.
The only exception may be in the group that discontinued
HBIG after a finite duration. Compared to the other three
groups, a lower percent of patients in this group had serum
HBV DNA >5 log10 copies/mL at transplant: 17.4% versus
42.0% (p = 0.056) but the percent of patients with virologic
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Figure 3: Post-OLT patient survival in patients with and with-
out HBV recurrence-–The 1, 3, and 5 year probability of post-
OLT patient survival was 100%, 85%, and 76% for patients
with; and 95% , 93%, and 92% for those without HBV recur-
rence (p = 0.028).
breakthrough prior to transplant was similar: 13.3% versus
19.1% (p = 0.583).
Despite the wide range in HBIG dosing, the HBV recur-
rence rate was comparable in the four groups (p = 0.733).
Comparison of the HBV recurrence rate in patients who
had stopped HBIG versus the other three groups com-
bined also showed no difference: 13% versus 6.2%, p =
0.439. These data have important implications regarding
cost savings. Using pharmacy charges at the University of
Michigan and the average amount of HBIG administered in
each group, the total charges for HBIG alone in year 1 were
$235 692, $191 099, $132 251 and $161 478 for the groups
that received indefinite IV high dose, IV low dose, IM low
dose and finite duration, respectively. The total charges for
HBIG in each subsequent year were $157 128, $44 712 and
$20 424 for the three groups that received indefinite HBIG,
while the total charges for HBIG decreased from $19 228
in year 2 to $0 in year 5 for the group that received a finite
duration of HBIG.
Our study spanned a 6.5 year period during which HBV ther-
apies changed from only one drug with a high rate of an-
tiviral resistance (lamivudine) to three approved HBV thera-
pies (lamivudine, ADV and ETV). Some of our patients were
listed for transplantation prior to the approval of lamivudine
and many were managed in an era when lamivudine was
the only approved HBV therapy. It is likely that use of more
potent nucleos(t)ide analogs that have a higher genetic bar-
rier to resistance prior to transplant, close monitoring for
virologic response, modification of treatment in patients
with suboptimal response, and prompt addition of rescue
therapy in patients with virologic breakthrough would re-
sult in a higher proportion of patients with undetectable
serum HBV DNA at the time of transplant and negligible
HBV recurrence rate may be achieved with minimal or no
HBIG. Indeed, Angus et al. (17) recently reported that none
of 16 patients randomized to switch from lamivudine +
HBIG to lamivudine + ADV had HBV recurrence after a me-
dian follow-up of 21 months. In this study, however, HBIG
was stopped after a mean of 4.5 years posttransplant. It
remains to be determined whether potent nucleos(t)ide
analogs that have high genetic barrier to resistance such
as ETV or TDF used alone or in combination will completely
eliminate the need for HBIG.
The strengths of this study are the large number of pa-
tients, the long duration of follow-up and HBV DNA testing
in a central laboratory. However, there are some limitations.
Most patients received lamivudine monotherapy as the ini-
tial antiviral therapy and rescue therapy was not available
during the earlier years. Furthermore, blood samples for
central laboratory testing were missing in some patients.
In summary, in this study involving 187 patients trans-
planted for HBV we found a wide range in HBIG regimens
among the 15 U.S. centers. However, HBV recurrence rate
was not related to HBIG regimen or transplant center. The
only factors associated with HBV recurrence were HBeAg
status at listing and serum HBV DNA level at transplant. Our
study showed that if appropriate rescue therapy is started
in patients with virologic breakthrough pre-OLT, compa-
rable results can be obtained with IM low dose or finite
course of HBIG as IV high dose HBIG. These data suggest
that substantially lower doses or a more limited duration of
HBIG than is currently used in many U.S. transplant centers
is sufficient in preventing HBV recurrence; this is particu-
larly true if more potent nucleos(t)ide analogs with higher
genetic barrier to resistance such as ETV or TDF are used.
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